Ananda Scientific

Ananda Scientific is a clinical-stage biopharmaceutical company advancing an innovative cannabinoid therapeutic to transform the treatment of neuropsychiatric health conditions. Our proprietary Liquid Structure™ delivery technology unlocks the true therapeutic potential of CBD by dramatically improving bioavailability, absorption consistency, and stability compared to existing formulations. Head-to-head studies against FDA-approved Epidiolex® shows Nantheia™ delivers higher peak concentrations of CBD in the bloodstream, with substantially reduced patient-to-patient dosage variability. Founded on rigorous science with clinical trials through NIH-funded research, our lead investigational drug, Nantheia™, is currently being studied in two, well-powered randomized PTSD clinical trials. In addition to PTSD, our pipeline addresses critical unmet medical needs across multiple other neuropsychiatric conditions including Social Anxiety Disorder, Opioid Addiction, Smoking Cessation and childhood epilepsy. With a seasoned management team bringing decades of pharmaceutical industry experience from companies such as Merck, Genzyme, Novartis, and Johnson & Johnson, Ananda has built a robust GxP-compliant manufacturing infrastructure and secured patent protection across 35+ global markets extending beyond 2040. We are committed to advancing evidence-based solutions that can meaningfully impact the lives of millions suffering from debilitating neuropsychiatric conditions.